SCHEMBL553117

SCHEMBL553117

CC(C)(C)C(=O)C(O)C(C)(C)C

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19387438 0.77 CA2 (0.33)
SCHEMBL8962464 0.77
SCHEMBL14664104 0.77
SCHEMBL7790012 0.75 ALDH1A1 (0.36) TSHR
SCHEMBL12234936 0.73 TSHR (0.33) TSHR
SCHEMBL13449774 0.73 TSHR (0.33) TSHR
SCHEMBL5493507 0.73 L3MBTL1 (0.32) TSHR
SCHEMBL2171251 0.73
SCHEMBL10120248 0.73 TP53 (0.33)
SCHEMBL20286469 0.73 TP53 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119072304-A Neuroactive steroids for the treatment of CNS related disorders 萨奇治疗股份有限公司 2024-12-03 CN claimed
CN-117384259-A Cell penetrating peptides based on influenza virus M2 proteins 中国医学科学院基础医学研究所 2024-01-12 CN claimed
US-20220372355-A1 METHOD FOR MAKING AGGLOMERATE PARTICLES MCARDLE JAMES L (US) 2022-11-24 US claimed
CN-116635452-B Free radically polymerizable crosslinking agent, curable composition, and adhesive therefrom 3M INNOVATIVE PROPERTIES CO. (US) 2026-05-26 CN disclosed
EP-4291953-B1 IMPROVED BLEACHING XETOS AG (DE) 2026-04-15 EP disclosed
US-12600885-B2 Composition including monomer with a carboxylic acid group, monomer with a hydroxyl group, an alkyl monomer, and crosslinker and related article and method 3M INNOVATIVE PROPERTIES COMPANY (US) 2026-04-14 US disclosed
US-12595393-B2 Curable compositions for forming light scattering layers 3M INNOVATIVE PROPERTIES COMPANY (US) 2026-04-07 US disclosed
US-12552896-B2 Ionic copolymer, curable membrane precursor composition, membrane composition, and electronic device 3M INNOVATIVE PROPERTIES COMPANY (US) 2026-02-17 US disclosed
US-12528158-B2 Abrasive article and method of making the same 3M INNOVATIVE PROPERTIES COMPANY (US) 2026-01-20 US disclosed
US-20250375084-A1 NON-SCRATCH ABRASIVE COMPOSITE AND ABRASIVE CLEANING ARTICLE 3M INNOVATIVE PROPERTIES COMPANY (US) 2025-12-11 US disclosed
EP-4658145-A1 ABRASIVE ARTICLE 3M Innovative Properties Company (US) 2025-12-10 EP disclosed
US-20090281099-A1 SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE ANDRES-GIL JOSE IGNACIO 2009-11-12 US disclosed
US-7524837-B2 Benzotriazapinone salts and methods for using same JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-28 US disclosed
US-7501418-B2 e.g. 3-[4-(2-Methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3H-2,5-dioxa-1,7-diaza-dicyclopenta[a,g]naphthalene; serotonine (5-HT) reuptake inhibitor, alpha 2-adrenoceptor antagonist; antidepressant, anxiolytic agent; Parkinson's disease, eating disorders, psychosis, obesity JANSSEN PHARMACEUTICA, N.V. (BE) 2009-03-10 US disclosed
US-20090023721-A1 Novel Substituted Tetracyclic Tetrahydrofuran, Pyrrolidine and Tetrahydrothiophene Derivatives and Their Use as a Medicament MEGENS ANTONIUS ADRIANUS HENDR 2009-01-22 US disclosed
US-7462717-B2 C6-and C9-substituted chromeno[4,3-c]isoxazoline derivatives and their use as anti-depressants JANSSEN PHARMACEUTICA N.V. (BE) 2008-12-09 US disclosed
US-20080108599-A1 Heterocyclic Tetracyclic Tetrahydrofuran Derivatives As 5Ht2 Inhibitors In The Treatment Of Cns Disorders JANSSEN-CILAG S.A. (ES) 2008-05-08 US disclosed
US-20080096925-A1 Novel Substituted 4-Phenyl-4[H-Imidazol-2-YL]-Piperidine Derivatived And Their Use As Selective Non-Peptide Delta Opioid Agonists JANSSEN PHARMACEUTICA N.V. (BE) 2008-04-24 US disclosed
US-7338949-B2 Mycobacterial inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-04 US disclosed
US-20070179167-A1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528158-B2 Abrasive article and method of making the same ITGAV, ILK, ITGA2 TSHR 4182/4885
US-20080108599-A1 Heterocyclic Tetracyclic Tetrahydrofuran Derivatives As 5Ht2 Inhibitors In The Treatment Of Cns Disorders HTR2C, HTR2A, TPH2 TSHR 262/4885
US-20090023721-A1 Novel Substituted Tetracyclic Tetrahydrofuran, Pyrrolidine and Tetrahydrothiophene Derivatives and Their Use as a Medicament HTR2C, HTR5A, TPH2 TSHR 268/4885
US-20090281099-A1 SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE ADRA2C, CHRNA5, ADRB2 TSHR 2130/4885
US-20080096925-A1 Novel Substituted 4-Phenyl-4[H-Imidazol-2-YL]-Piperidine Derivatived And Their Use As Selective Non-Peptide Delta Opioid Agonists OPRD1, OPRK1, OPRL1 TSHR 354/4885
US-12595393-B2 Curable compositions for forming light scattering layers CRY2, FLNB, CDH1 TSHR 2938/4885
US-20070179167-A1 Inhibitors of serine proteases PRSS1, PRSS3, PRSS2 TSHR 4684/4885
US-12552896-B2 Ionic copolymer, curable membrane precursor composition, membrane composition, and electronic device VMA21, PLA2G2A, ARCN1 TSHR 2529/4885
US-12600885-B2 Composition including monomer with a carboxylic acid group, monomer with a hydroxyl group, an alkyl monomer, and crosslinker and related article and method RAD51, HACL2, COL2A1 TSHR 3374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.